<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924192</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3616-ALTN-II-01</org_study_id>
    <nct_id>NCT04924192</nct_id>
  </id_info>
  <brief_title>A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer</brief_title>
  <official_title>A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of&#xD;
      TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the&#xD;
      treatment of advanced lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The time when the participants first achieved CR or PR to disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month progression-free survival rate</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month and 12-month overall survival rate</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Advanced Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>TQB3616 capsules+Anlotinib hydrochloride capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB3616 capsules +Irinotecan Hydrochloride for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3616 capsules</intervention_name>
    <description>A CDK4/6 kinase inhibitor</description>
    <arm_group_label>TQB3616 capsules +Irinotecan Hydrochloride for Injection</arm_group_label>
    <arm_group_label>TQB3616 capsules+Anlotinib hydrochloride capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride capsules</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB3616 capsules+Anlotinib hydrochloride capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride for Injection</intervention_name>
    <description>An inhibitor of DNA topoisomerase Ⅰ</description>
    <arm_group_label>TQB3616 capsules +Irinotecan Hydrochloride for Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with pathologically proven small cell lung cancer(SCLC) or/and locally&#xD;
             advanced ( Stage ⅢB/ ⅢC), metastatic or recurrent (Stage IV) non small cell lung&#xD;
             cancer(NSCLC).&#xD;
&#xD;
          2. Cohort 1: Subjects with SCLC who had previously received at least one chemotherapy&#xD;
             containing platinum or got disease progression during chemoradiotherapy or after the&#xD;
             last treatment.&#xD;
&#xD;
          3. Cohort 2: Subjects with locally advanced, metastatic/relapsed NSCLC who had previously&#xD;
             received only one PD (L) 1 inhibitor alone or in combination with platinum-based&#xD;
             chemotherapy.&#xD;
&#xD;
          4. Subjects with measurable lesions as defined by RECIST 1.1.&#xD;
&#xD;
          5. Aged ≥ 18 years ; Eastern Cooperative Oncology Group (ECOG) score: 0 ~ 1; Expected&#xD;
             survival ≥ 3 months.&#xD;
&#xD;
          6. Laboratory indicators meet the requirements.&#xD;
&#xD;
          7. Non-pregnant or non-breastfeeding women; Negative pregnancy subjects.&#xD;
&#xD;
          8. Subjects voluntarily joined the study and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who received prior therapy with anlotinib hydrochloride capsules.&#xD;
&#xD;
          2. Cohort 2: Subjects with epidermal growth factor receptor(EGFR) mutation and anaplastic&#xD;
             lymphoma kinase(ALK) translocation.&#xD;
&#xD;
          3. Subjects with central squamous cell carcinoma with a risk of hemoptysis.&#xD;
&#xD;
          4. Subjects who have developed or is currently suffering from other malignancies within 5&#xD;
             years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in&#xD;
             situ.&#xD;
&#xD;
          5. Subjects who have brain metastases with symptoms or control of symptoms for less than&#xD;
             2 months.&#xD;
&#xD;
          6. Subjects with difficulty taking oral medication.&#xD;
&#xD;
          7. Subjects with uncontrolled pleural effusion, pericardial effusion or ascites requiring&#xD;
             repeated drainage.&#xD;
&#xD;
          8. Subjects with spinal cord compression who have failed to be cured or relieved by&#xD;
             surgery and or radiotherapy.&#xD;
&#xD;
          9. Subjects who have received chemotherapy, radiotherapy or other experimental anticancer&#xD;
             therapy within 4 weeks prior to the first dose of the drug.&#xD;
&#xD;
         10. Subjects who have not recovered to ≤ CTCAE Grade 1 (excluding alopecia) due to the&#xD;
             adverse event of prior therapy.&#xD;
&#xD;
         11. Subjects with significant surgery or significant traumatic injury within 28 days&#xD;
             before randomization.&#xD;
&#xD;
         12. Subjects with arterial/venous thrombosis within 6 months.&#xD;
&#xD;
         13. Subjects with a history of psychotropic substance abuse who cannot be withdrawn or&#xD;
             have mental disorders.&#xD;
&#xD;
         14. Subjects with any severe and/or uncontrolled disease.&#xD;
&#xD;
         15. Subjects whose large vessels are involved by tumor from imaging (CT or MRI).&#xD;
&#xD;
         16. Subjects who have hemoptysis and maximum daily hemoptysis ≥ 2.5ml within 1 month&#xD;
             before the first dose.&#xD;
&#xD;
         17. Subjects with other factors that might cause the study to be terminated halfway per&#xD;
             the judgement of the investigator.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongsheng Li, Doctor</last_name>
    <phone>18980602258</phone>
    <email>wangys@wchscu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianghong Wang, Master</last_name>
      <phone>13983841209</phone>
      <email>wjhwin16@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Yue, Master</last_name>
      <phone>13893265368</phone>
      <email>13893289062@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Zhang, Doctor</last_name>
      <phone>18885146684</phone>
      <email>248634489@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of PLA Air Force Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haichuan Su, Doctor</last_name>
      <phone>18629190366</phone>
      <email>cntdgcp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdou</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Li, Doctor</last_name>
      <phone>18980602258</phone>
      <email>wangys@wchscu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenxiu Yao, Doctor</last_name>
      <phone>18908178836</phone>
      <email>ywxhlx@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runxiang Yang, Doctor</last_name>
      <phone>13888876721</phone>
      <email>13888876721@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

